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Serum Kisspeptin Levels in Korean Girls with Central Precocious 
Puberty
Central precocious puberty (CPP) is caused by premature activation of hypothalamic 
gonadotropin-releasing hormone (GnRH) secretion. Kisspeptin and G-protein coupled 
receptor-54 system is the essential gatekeeper of the reproductive system, playing a key 
role in the activation of the gonadotropic axis at puberty. We aimed to determine whether 
serum kisspeptin may function as a marker for CPP by investigating serum kisspeptin levels 
in Korean girls with CPP and their prepubertal controls. Serum kisspeptin levels of Korean 
girls with CPP (n = 30) and age-matched healthy prepubertal controls (n = 30) were 
measured with a competitive enzyme immunoassay. Serum kisspeptin levels were 
significantly higher in CPP group than in control group (4.61 ± 1.78 vs 2.15 ± 1.52 pM/L, 
P < 0.001). Serum kisspeptin was positively correlated with peak luteinizing hormone (LH), 
peak/basal LH ratio and peak LH/follicular-stimulating hormone (FSH) ratio during GnRH 
stimulation test. CPP is supposed to be triggered by premature increase of kisspeptin. 
Serum kisspeptin may be used as a marker of CPP. Further studies on KISS1 gene 
polymorphisms leading to higher risk of premature increase of kisspeptin and upstream 
regulator of kisspeptin are also needed.
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INTRODUCTION
Puberty is a complex and coordinated biologic process of sexu-
al development that lead to complete gonadal maturation and 
function, and attainment of reproductive capacity. The activa-
tion of pulsatile gonadotropin-releasing hormone (GnRH) se-
cretion from specialized hypothalamic neurons to stimulate 
hormonal cascades and gonadal activation is a key event in the 
onset of puberty (1). But, the ultimate mechanisms underlying 
the increase in pulsatile GnRH seceretion at puberty are yet to 
be fully elucidated (2). 
  The kisspeptin, the peptide product of KISS1 gene and its pu-
tative receptor G protein coupled receptor-54 (GPR54) signaling 
complex has recently emerged as essential gatekeeper of puber-
tal activation of GnRH neurons and the reproductive axis, and 
it has been the focus of intense study by investigators (3-7). An 
increase in kisspeptin signaling which is caused by enhanced 
expression of KISS1 and GPR54 at the time of puberty contrib-
utes to, or even drives, the activation of the gonadotropic axis dur-
ing pubertal development (8). Kisspeptin is a powerful stimulus 
for GnRH-induced gonadotropin secretion. Kisspeptin adminis-
tration to immature animals was able to induce precocious ac-
tivation of the gonadotropic axis and pubertal development (9). 
  Precocious puberty is defined as the development of second-
ary sexual characteristics before the age of 8 yr for girls and 9 yr 
for boys (10). Central precocious puberty (CPP) is defined if the 
process is driven by premature activation of hypothalamic GnRH 
secretion. Early diagnosis and treatment of CPP is important to 
improve final height because CPP can cause early epiphyseal 
maturation with compromised final height as well as psycholog-
ical stress (11). So far, GnRH stimulation test is considered the 
definite biochemical parameter for diagnosis of CPP. It is highly 
specific but its sensitivity is low (12-14). We assumed that serum 
kisspeptin level may be higher in girls with CPP than in prepu-
bertal girls because hypothalamic kisspeptin signaling increases 
in the onset of puberty. Up to date, no data on serum kisspeptin 
levels in Korean girls with CPP are available. This study was aimed 
to determine whether serum kisspeptin may function as a mark-
er for CPP by investigating serum kisspeptin levels in Korean 
girls with CPP and healthy prepubertal controls. 
MATERIALS AND METHODS
The subjects consisted of two groups : Korean girls with CPP and 
healthy prepubertal controls. Subjects with CPP (n = 30) were 
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University Ansan Hospital. They were between 6 and 9 yr old. 
They were diagnosed according to the same criteria: 1) The pa-
tients all should show Tanner breast stage scores ≥ 2 based on 
standardized Tanner breast stage assessment before the age         
of 8 yr, 2) bone age assessed by a single observer according to 
Greulich and Pyle method should be found to be at least 1 yr 
ahead of their chronological age, 3) significantly higher peak 
luteinizing hormone (LH) values comparing with the cut-off 
value of 5 IU/L under the GnRH stimulation test conducted pri-
or to the age of 9 yr. To exclude other forms of precocious puber-
ty, further laboratory and imaging studies were performed ac-
cording to clinical judgment. CPP patients with identified etiol-
ogy, such as brain tumor or cranial irradiation, were excluded. 
CPP patients who had been treated with GnRH agonist were ex-
cluded. The control group (n = 30) consisted of age-matched 
healthy prepubertal girls. They were recruited from prepubertal 
girls who visited the outpatient clinic of Department of Pediat-
rics, Korea University Ansan Hospital. They were recruited as 
volunteers.
  Measurements of height and weight were performed in all 
subjects. Body mass index (BMI) was calculated as the weight 
in kilograms divided by the square of height in meters. The pu-
bertal stage of each subject was determined by one pediatric en-
docrinologist and rated according to the Tanner criteria (15). 
  Blood was collected into a lavender vacutainer tube contain-
ing EDTA at 4°C (2.5 mL of blood for each subject). The blood 
was transferred from the lavender vacutainer tube to the centri-
fuge tube. We centrifuged the blood for 15 min at 4°C and collect-
ed the plasma. The plasma was kept at -70°C until all samples 
were collected. The peptide was extracted using SEP-COLUMN 
(Strata, Phenomenex, Torrance, CA, USA) containing 200 mg of 
C18. The concentration of kisspeptin was measured using Kiss-
peptin-10 (Metastin [45-54]-Amide) and competitive enzyme 
immunoassay (Kit# EK-048-56, Phoenix Pharmaceuticals, Inc., 
Burlingame, CA, USA). The method was described in the prod-
uct insert. Fifty-five microliters of plasma with 25 μL of primary 
antibody and 25 μL of biotinylated peptide were incubated at 
room temperature for 2 hr. Then, 0.1 mL of streptavidin-horse-
radish peroxidase solution was added. After incubation for 1 hr 
at room temperature, 0.1 mL of chemical name TMB substrate 
solution was added. One hour later for incubation at room tem-
perature, the reaction was stopped with 0.1 mL of 2N HCl. After 
loading the immunoplate onto a microtiter plate reader, we read 
the absorbance at 450 nm. All measurements were in duplicates 
and average was calculated.
  The GnRH stimulation test was conducted in all subjects. Bas-
al serum samples were obtained prior to GnRH injection. GnRH 
(0.1 mg) was administered intravenously for 1 min and post-stim-
ulation samples were taken at 30, 60, and 90 min after injection 
for measurements of LH and follicle-stimulating hormone (FSH) 
levels.
  The SPSS 16.0 software package (SPSS Inc.; Chicago, IL) was 
used to perform statistical analyses. Data are expressed as mean 
± standard deviation (SD). Independent t-test and Pearson’s cor-
relation test were used for data analysis and P values of < 0.05 
were considered statistically significant.
Ethics statement
This study was approved by the Institutional Review Board of 
Korea University Ansan Hospital in Gyeonggi-do, Korea (IRB 
number AS10036). Written informed consents were obtained 
from all subjects and their parents. 
RESULTS
Serum kisspeptin, clinical characteristics and the results of GnRH 
stimulation test of CPP and control groups are shown in Table 1. 
Serum kisspeptin levels were significantly higher in CPP group 
than in control group (4.61 ± 1.78 vs 2.15 ± 1.52 pM/L, P < 0.001). 
CPP group also had significantly higher bone age, bone age ad-
vancement, peak LH, peak/basal LH ratio, basal FSH, basal and 
peak FSH, peak/basal FSH ratio and peak LH/FSH ratio com-
pared with control group. There were no significant differences 
in age, height, weight, BMI, basal LH and basal LH/FSH ratio 
between CPP and control groups.
  The correlations between serum kisspeptin and other clini-
cal characteristics and the results of GnRH stimulation test are 
shown in Table 2. Serum kisspeptin was positively correlated 
with bone age, bone age advancement, peak LH, peak/basal LH 
ratio and peak LH/FSH ratio. No correlations were found be-
tween kisspeptin and age, height, weight, BMI, basal LH, basal 
and peak FSH, peak/basal FSH ratio and basal LH/FSH ratio.
Table 1. Comparison of serum kisspeptin level, clinical characteristics and the results 
of GnRH stimulation test between central precocious puberty and control groups
Variables    CPP (n = 30)    Control (n = 30) P value
Kisspeptin (pM/L)      4.61 ± 1.78     2.15 ± 1.52 < 0.001
Age (yr)      8.34 ± 1.04     8.04 ± 0.67 0.173
BA (yr)    10.44 ± 0.74     8.21 ± 0.63 < 0.001
BA-CA (yr)      2.07 ± 0.66     0.17 ± 0.56 < 0.001
Height (cm) 130. 7 ± 9.9 129.2 ± 7.0 0.547
Weight (kg)    32.7 ± 9.1   30.8 ± 6.5 0.412
BMI (kg/m
2)    18.8 ± 3.2   18.3 ± 2.9 0.637
Basal LH (IU/L)      0.36 ± 0.71     0.12 ± 0.22 0.203
Peak LH (IU/L)      13.62 ± 13.48     2.36 ± 1.16 < 0.001
Peak/basal LH ratio      66.17 ± 32.06     30.76 ± 16.60 0.001
Basal FSH (IU/L)      2.63 ± 1.14     1.46 ± 0.80 < 0.001
Peak FSH (IU/L)    16.19 ± 6.04   12.24 ± 3.76 0.011
Peak/basal FSH ratio      6.78 ± 2.59     9.85 ± 3.61 0.005
Basal LH/FSH ratio      0.14 ± 0.27     0.07 ± 0.06 0.362
Peak LH/FSH ratio      0.97 ± 0.99     0.21 ± 0.14 0.008
Data are shown as mean ± standard deviation. CPP, central precocious puberty; BA, 
bone age; CA, chronological age; BA-CA, bone age advancement, BMI, body mass 
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DISCUSSION
To the best of our knowledge, this is the first study on serum kis-
speptin levels in Korean girls with CPP or in healthy prepuber-
tal girls. In this study, we demonstrated that serum kisspeptin 
level was significantly higher in girls with CPP than in their age-
matched prepubertal controls. This was in accordance with the 
first report on the serum kisspeptin level in prepubertal girls and 
in girls with CPP in 2009 (16). We also found that serum kiss-
peptin was positively correlated with peak LH, peak/basal LH 
ratio and peak LH/FSH ratio during GnRH stimulation test. These 
findings suggest that serum kisspeptin level is associated with 
LH increase during GnRH stimulation test. Accordingly, serum 
kisspeptin may be used as an adjunctive marker for CPP because 
the diagnosis of CPP is based on the peak LH level during GnRH 
stimulation test. Moreover, it is suggested that CPP is triggered 
by premature increase of kisspeptin and subsequent activation 
of hypothalamic-pituitary-gonadal axis.
  The indispensable role of kisspetin and GPR54 in the control 
of puberty is now well established. KISS1 gene was first discov-
ered in 1996, and has been mapped to the long arm of chromo-
some 1q32. This gene consists of three exons, of which only part 
of the second and third exons are finally translated into a 145- 
amino acid precursor peptide (17). This precursor is then cleaved 
into three forms of kisspeptins containing 54, 14, and 13 amino 
acids. The three peptides exhibit the same affinity for the recep-
tor since they share a common C-terminal decapeptide desig-
nated kisspeptin-10 (4, 7). 
  Kisspeptin is extraordinary potent elicitor of LH and FSH re-
lease, either after intracerebral or systemic administration of the 
peptide (8, 18-20). The sensitivity of LH release to the stimulato-
ry effect of kisspeptin is very high (20, 21). Notably, FSH release 
in vivo appeared to be approximately 100-fold less sensitive to 
the stimulatory effect of kisspeptin than LH (19). Our findings 
that serum kisspeptin level is associated with LH increase, but 
not with FSH increase during GnRH stimulation test are in con-
cordance with these results.
  Gonadotropin-releasing effect of kisspeptin comes from the 
ability to activate GnRH release at the hypothalamus. Kisspeptin-
induced membrane excitability on GnRH neurons was increased 
after puberty in mice (22). Activating GPR54 by kisspeptin trig-
gers a phospholipase C-inositol triphosphate receptor-calcium 
cascade to initiate depolarization in GnRH neurons (23). More 
than 75% of GnRH neuron in the rat hypothalamus co-express 
GPR54 mRNA and central administration of kisspeptin induced 
c-fos expression (as early marker of activation) in more than 85% 
of GnRH neurons (24). Therefore, it has been strongly suggested 
that kisspeptin directly activates hypothalamic GnRH neurons, 
causing stimulation of GnRH secretion, which in turn elicits LH 
and FSH release from the pituitary (25). Notwithstanding the 
reports that systemic administration of kisspeptin induced LH 
and FSH release in animal studies (8, 26), it is not certain wheth-
er serum kisspeptin has an effect on the direct activation on hy-
pothalamic GnRH neuron at the onset of puberty along with 
hypothalamic kisspeptin. Expression of KISS1 gene was dem-
onstrated not only in brain but also in placenta, testis and small 
intestine (27, 28). Thus, it is assumed that there may be upstream 
regulatory factors of kisspeptin, which augment KISS1 gene ex-
pression not only in hypothalamus but also in other tissues at 
onset of puberty and consecutively serum kisspeptin level is in-
creased. This assumption requires further investigation.
  Serum kisspeptin may be used as a marker of CPP. A possible 
limitation of this study was that the sample size was relatively 
small. Therefore, our findings should be validated by large-scaled 
studies. Further studies on KISS1 gene polymorphisms leading 
to higher risk of premature increase of kisspeptin and on up-
stream regulator of kisspeptin are also needed.
  In conclusion, serum kisspeptin level is higher in Korean girls 
with CPP than in age-matched prepubertal controls and CPP is 
supposed to be triggered by premature increase of kisspeptin. 
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